Literature DB >> 26366936

Prevalence of Pulmonary Hypertension and its Influence on Survival in Patients With Advanced Chronic Obstructive Pulmonary Disease Prior to Lung Transplantation.

Don Hayes1,2,3, Sylvester M Black4, Joseph D Tobias5,6, Heidi M Mansour7, Bryan A Whitson4.   

Abstract

INTRODUCTION: Prevalence of pulmonary hypertension (PH) and its influence on survival in chronic obstructive pulmonary disease (COPD) are not well studied in the lung allocation score (LAS) era.
METHODS: The UNOS database was queried from 2005 to 2013 to identify first-time adult lung transplant candidates with COPD who were tracked from wait list entry date until death or censoring to determine both prevalence and influence of PH. Using right heart catheterization measurements, mild PH was defined as mean pulmonary artery pressure (mPAP) ≥ 25 mmHg and severe ≥ 35 mmHg.
RESULTS: Of 1315 COPD candidates not transplanted, 1243 were used for survival analysis using Cox proportional hazards models, and 1010 (mild PH) and 244 (severe PH) were used for propensity score matching, respectively. A total of 52% (652) of subjects had PH mPAP ≥ 25 mmHg. Univariate analysis revealed significant differences in survival for mild PH (HR = 1.769; 95% CI: 1.331, 2.351; p < 0.001) and severe PH (HR = 3.271; 95% CI: 2.311, 4.630; p < 0.001). Kaplan-Meier survival function demonstrated significant disparities for mild PH (Log-rank test: Chi-square1: 15.87, p < 0.0001) and severe PH (Log-rank test: Chi-square1: 50.13, p < 0.0001). Multivariate Cox models identified significant risk for death for mild PH (HR = 1.987; 95% CI: 1.484, 2.662; p < 0.001) and severe PH (HR = 3.432; 95% CI: 2.410, 4.888; p < 0.001). Propensity score matching confirmed increased mortality hazard associated with mild PH (HR = 2.280; 95% CI: 1.425, 3.649; p = 0.001) and severe PH (HR = 7.000; 95% CI: 2.455, 19.957; p < 0.001).
CONCLUSIONS: PH is highly prevalent in advanced COPD and associated with a significantly higher risk for mortality.

Entities:  

Keywords:  chronic obstructive pulmonary disease; lung transplantation; pulmonary hypertension; survival

Mesh:

Year:  2015        PMID: 26366936     DOI: 10.3109/15412555.2015.1043425

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  12 in total

Review 1.  Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions.

Authors:  Faisal M Siddiqui; Joshua M Diamond
Journal:  Curr Opin Pulm Med       Date:  2018-03       Impact factor: 3.155

Review 2.  The Intersection of Pulmonary Hypertension and Solid Organ Transplantation.

Authors:  Adaani E Frost
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

3.  Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.

Authors:  Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos
Journal:  J Heart Lung Transplant       Date:  2021-07-24       Impact factor: 13.569

4.  Effect of pulmonary hypertension on exercise capacity and gas exchange in patients with chronic obstructive pulmonary disease living at high altitude.

Authors:  Mauricio Gonzalez-Garcia; Carlos Eduardo Aguirre-Franco; Leslie Vargas-Ramirez; Margarita Barrero; Carlos A Torres-Duque
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

5.  Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.

Authors:  Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai
Journal:  Chest       Date:  2020-03-14       Impact factor: 9.410

6.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

7.  Pulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation.

Authors:  Enric Domingo; Juan C Grignola; Rio Aguilar; Manuel López Messeguer; Antonio Roman
Journal:  Respir Res       Date:  2017-05-06

8.  Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy.

Authors:  Maria F Acosta; Priya Muralidharan; Carissa L Grijalva; Michael D Abrahamson; Don Hayes; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 5.158

9.  Design and development of innovative microparticulate/nanoparticulate inhalable dry powders of a novel synthetic trifluorinated chalcone derivative and Nrf2 agonist.

Authors:  Priya Muralidharan; Brielle Jones; Graham Allaway; Shyam S Biswal; Heidi M Mansour
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.996

10.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:  Maria F Acosta; Michael D Abrahamson; David Encinas-Basurto; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.